562 related articles for article (PubMed ID: 31779484)
1. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
Zhao H; Li Y; He L; Pu W; Yu W; Li Y; Wu YT; Xu C; Wei Y; Ding Q; Song BL; Huang H; Zhou B
Circulation; 2020 Jan; 141(1):67-79. PubMed ID: 31779484
[TBL] [Abstract][Full Text] [Related]
2. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
Jarrett KE; Lee C; De Giorgi M; Hurley A; Gillard BK; Doerfler AM; Li A; Pownall HJ; Bao G; Lagor WR
Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
[TBL] [Abstract][Full Text] [Related]
4. Exosome-based
Li Z; Zhao P; Zhang Y; Wang J; Wang C; Liu Y; Yang G; Yuan L
Theranostics; 2021; 11(6):2953-2965. PubMed ID: 33456582
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Gene Editing in Lipid and Atherosclerosis Research.
De Giorgi M; Jarrett KE; de Aguiar Vallim TQ; Lagor WR
Methods Mol Biol; 2022; 2419():673-713. PubMed ID: 35237996
[TBL] [Abstract][Full Text] [Related]
6. LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis.
Guo X; Gao M; Wang Y; Lin X; Yang L; Cong N; An X; Wang F; Qu K; Yu L; Wang Y; Wang J; Zhu H; Xian X; Liu G
EBioMedicine; 2018 Jan; 27():214-224. PubMed ID: 29289533
[TBL] [Abstract][Full Text] [Related]
7. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ
Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor (LDLR) on exon 7.
Lu R; Yuan T; Wang Y; Zhang T; Yuan Y; Wu D; Zhou M; He Z; Lu Y; Chen Y; Fan J; Liang J; Cheng Y
EBioMedicine; 2018 Oct; 36():29-38. PubMed ID: 30243490
[TBL] [Abstract][Full Text] [Related]
9. Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease.
Jarrett KE; Lee CM; Yeh YH; Hsu RH; Gupta R; Zhang M; Rodriguez PJ; Lee CS; Gillard BK; Bissig KD; Pownall HJ; Martin JF; Bao G; Lagor WR
Sci Rep; 2017 Mar; 7():44624. PubMed ID: 28300165
[TBL] [Abstract][Full Text] [Related]
10. Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats.
Zhao Y; Yang Y; Xing R; Cui X; Xiao Y; Xie L; You P; Wang T; Zeng L; Peng W; Li D; Chen H; Liu M
Atherosclerosis; 2018 Apr; 271():26-35. PubMed ID: 29459263
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Systems Suitable for Single AAV Vector Delivery.
Stevanovic M; Piotter E; McClements ME; MacLaren RE
Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
[TBL] [Abstract][Full Text] [Related]
12. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
13. Generation of hyperlipidemic rabbit models using multiple sgRNAs targeted CRISPR/Cas9 gene editing system.
Yuan T; Zhong Y; Wang Y; Zhang T; Lu R; Zhou M; Lu Y; Yan K; Chen Y; Hu Z; Liang J; Fan J; Cheng Y
Lipids Health Dis; 2019 Mar; 18(1):69. PubMed ID: 30885208
[TBL] [Abstract][Full Text] [Related]
14. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
15. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.
Srivastava RAK
Cells; 2023 Jun; 12(12):. PubMed ID: 37371118
[TBL] [Abstract][Full Text] [Related]
16. New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing.
Srivastava RAK
Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2317-2325. PubMed ID: 37805309
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting
Lee RG; Mazzola AM; Braun MC; Platt C; Vafai SB; Kathiresan S; Rohde E; Bellinger AM; Khera AV
Circulation; 2023 Jan; 147(3):242-253. PubMed ID: 36314243
[TBL] [Abstract][Full Text] [Related]
18. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.
Song CQ; Wang D; Jiang T; O'Connor K; Tang Q; Cai L; Li X; Weng Z; Yin H; Gao G; Mueller C; Flotte TR; Xue W
Hum Gene Ther; 2018 Aug; 29(8):853-860. PubMed ID: 29597895
[TBL] [Abstract][Full Text] [Related]
20. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
